## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )\*

## Virios Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

92829J104 (CUSIP Number)

			December 31, 2020 (Date of Event Which Requires Filing of this Statement)						
Checl	k the appro	opriate box t	to designate the rule pursuant to which this Schedule is filed:						
		Rule 13d-	4-1(b)						
		Rule 13d-	1-1(c)						
	X	Rule 13d-	1-1(d)						
			ver page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsection which would alter disclosures provided in a prior cover page.	quent					
The in	nformation wise subje	n required or ect to the liab	on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (abilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).	("Act") or					
	dule 13G		Page	e 2 of 5 Pages					
CUSI	IP NO. <u>928</u>	829J104							
1.	Names	Names of Reporting Persons							
	Gregor	ry Duncan							
2.	Check	the Appropr	priate Box if a Member of a Group (See Instructions)						
	(a) (b)								
3.	SEC U	JSE ONLY							
4.		nship or Plac	ace of Organization						
Sha		5.	Sole Voting Power 439,825 shares						
Beneficially Owned by Each Reporting Person With		6.	Shared Voting Power None						
		7.	Sole Dispositive Power 439,825 shares						
		8.	Shared Dispositive Power None						

Aggregate Amount Beneficially Owned by Each Reporting Person 9.

10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □								
11.	Perc	Percent of Class Represented by Amount in Row (9)* 5.03%							
	5.03								
12.	Type of Reporting Person (See Instructions) IN								
Schedule	a 130	7			Page 3 of 5 Page				
			1		rage 3 of 3 rage				
Item 1.(		D. 92829J104  Name of Issuer:							
rem i.(	u)			es Inc					
<u>Item 1</u> .(	Virios Therapeutics, Inc.  b) Address of Issuer's Principal Executive Offices:								
	ĺ	44 Milto	on Avenue						
	Alpharetta, GA 30009								
Item 2.(	a)	Name of Person Filing:							
		Gregory Duncan							
Item 2.(	b)	Address of Principal Business Office or, if none, Residence							
		44 Milton Avenue Alpharetta, GA 30009							
<u>Item 2</u> .(	c)	<u>Citizenship</u> :							
		United States							
<u>Item 2</u> .(	d)	Title of Class of Securities:							
		Common Stock, par value \$0.0001 per share							
<u>Item 2</u> .(	e)	) <u>CUSIP Number</u> :							
		92829J104							
Item 3.		If this st	tatement is	filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:					
		(a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k)		Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).  An employee benefit plan or endowment fund in accordance with §240.13d-(b)(1)(ii)(F).  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Com (15 U.S.C. 80a-3).  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).  Group, in accordance with §240.13d-(b)(1)(ii)(K).	pany Act of 1940				
		Not app	licable.						

Schedule 13G Pages 4 of 5 Pages

## CUSIP NO. <u>92829J104</u>

## Item 4. Ownership.

	(c)	Numbe	er of shares as to which such person has:				
		(i) (ii) (iii) (iv)	Sole power to vote or to direct the vote: 439,825 (1) Shared power to vote or to direct the vote: 0 Sole power to dispose or to direct the disposition of: 439,825 (1) Shared power to dispose or to direct the disposition of: 0				
options t	o which the r	eporting p	able pursuant to an outstanding warrant which warrant was exercised prior to the filing of this report, and (ii) 435,921 shares underlying stock erson was entitled pursuant to his employment agreement with the Issuer dated April 5, 2020 and which are currently exercisable. The preported in this Schedule 13G is based upon 8,305,075 shares of common stock of the issuer outstanding.				
Item 5.	15. Ownership of Five Percent or Less of a Class.						
			s being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the check the following. $\Box$				
Item 6.	Ownership of More than Five Percent on Behalf of Another Person						
	Not applicable.						
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person						
	Not applicable.						
Item 8.	Identification and Classification of Members of the Group.						
	Not app	olicable.					
Item 9.	Notice of Dissolution of Group.						
	Not app	olicable.					
Schedule	e 13G		Page 5 of 5 Pages				
CUSIP N	NO. <u>92829J10</u>	<u>)4</u>					
<u>Item 10</u> .	Certific	cations.					
	Not app	olicable.					
			SIGNATURE				
	After reason	able inquir	y and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.				
Date:	February 16,	, 2021	/s/ Gregory Duncan				
			Gregory Duncan				

(b)

Percent of Class: 5.03% (2)